Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion

US6492106B1 · kind B1 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• David M. Sabatini · Cambridge, US
• Hediye Erdjument-Bromage · New York, US
• Mary Lui · Elmont, US
• Paul Tempst · New York, US
• Solomon H. Snyder · Baltimore, US

Key dates

• Filing date: Sep 14, 1994
• Grant date: Dec 10, 2002
• Expiry date: Sep 14, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N9/1205
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A protein complex containing 245 kDa and 35 kDa components, designated RAFT1 and RAFT2 (for Rapamycin And FKBP12 Target) interacts with FKBP12 in a rapamycin-dependent manner. This interaction has the pharmacological characteristics expected from the observed in vivo effects of rapamycin: it occurs at low nanomolar concentrations of rapamycin and is competed by excess FK506. Sequences (330 amino acids total) of tryptic peptides derived from the affinity purified 245 kDa RAFT1 reveals striking homologies to the predicted products of the yeast TOR genes, which were originally identified by mutations that confer rapamycin resistance in yeast. A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2550 amino acids) that is 43% and 39% identical to TOR2 and TOR1, respectively.